Association between a functional polymorphism rs10830963 in *melatonin receptor 1B* and risk of gestational diabetes mellitus: an updated meta-analysis

Yu Xiangyuan¹, Wang Qianqian¹, Qin Linyuan¹, Peng Lingxiang², Chen Zaiming³, Qin Xiumei⁴, Wang Yuchun⁴, Shi Qingfeng², Yu Hongping^{5*}

¹Department of Epidemiology & Statistics, School of Public Health, Guilin Medical University, Guilin, 541004, P.R. China;

²Department of Obstetrics, The First Affiliated Hospital of Guilin Medical University, Guilin, 541001, P.R. China;

³Lingchuan People's Hospital, Guilin, 541299, P.R. China;

⁴Department of Obstetrics, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, P.R. China;

⁵Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021, P.R. China.

The first two authors contributed equally to this work and should be considered as co-first authors.

*Correspondence: Yu Hongping, yhp268@163.com

Abstract

The *melatonin receptor 1B* (*MTNR1B*) as a candidate gene for gestational diabetes mellitus (GDM) on the basis of its association with T2DM, β -cells function and fasting plasma glucose (FPG) level. Many studies have investigated the association between *MTNR1B* polymorphism rs10830963 C>G and GDM risk, but the conclusion is inconsistent. PubMed, Google Scholar and CNKI databases were searched to identify eligible studies. Pooled OR with corresponding 95% CI was used to estimate the strength of the association between rs10830963 and GDM risk using a fixed- or random-effect model. 12 eligible studies with a number of 4,782 GDM patients and 5,605 controls were included in this meta-analysis. Results indicated that the variant G allele of rs10830963 polymorphism was significantly associated with an increased risk of GDM (CG vs. CC: OR=1.23, 95% CI = 1.12–1.34, $P_{\text{heterogeneity}} = 0.23$; GG vs. CC: OR=1.74, 95% CI = 1.41–2.15, $P_{\text{heterogeneity}} = 0.002$). In the stratified analysis by ethnicity, similar results were found in Asians (CG vs. CC: OR=1.15, 95% CI

=1.04–1.28, $P_{\text{heterogeneity}} = 0.74$; GG vs. CC: OR=1.48, 95% CI=1.23–1.78, $P_{\text{heterogeneity}} = 0.08$) and in Caucasians (CG vs. CC: OR=1.49, 95% CI=1.25–1.77, $P_{\text{heterogeneity}} = 0.28$; GG vs. CC: OR=2.68, 95% CI=2.03–3.54, $P_{\text{heterogeneity}} = 0.58$).

Introduction

Gestational diabetes mellitus (GDM) is defined as abnormal glucose tolerance with onset or first recognition during pregnancy¹. Worldwide, it affects approximately 2~20% of all pregnancies². GDM has been shown to be associated with poor pregnancy outcome and substantial long-term adverse consequences for mothers and their offspring³⁻⁶. So far, the major risk factors related to GDM are older age at pregnancy, obesity, family history of T2DM and past history of GDM, previous poor obstetric history and genetics⁷⁻¹³. Insulin secretory defect accompanied by peripheral insulin resistance is an important characteristic of GDM¹². Melatonin receptor 1B (MTNR1B) is an integral membrane protein that coupled to an inhibitory G protein and is expressed in pancreatic islets and pancreatic β -cells^{13,14}. It has been found that the increased expression of MTNR1B on β -cells diminished intracellular cyclic cAMP levels, thereby inhibited the insulin secretion^{15,16}. These findings suggested that MTNR1B may be involved in the development of GDM.

MTNR1B is located on human chromosome 11q21-q22, spanning about 22 kb and consisting of 3 exons and 1 intron. So far, 64 single nucleotide polymorphisms (SNPs) have been validated in the *MTNR1B* gene (<http://www.ncbi.nlm.nih.gov/SNP>), and some of which were reported to be associated with GDM risk. The SNP rs10830963 is located in the unique intron between exon 1 (+5.6 kb) and exon 2 (–5.9kb) of *MTNR1B* gene. Genotype-phenotype study of the SNP rs10830963 C>G showed that compared with the wild-type C allele of rs10830963, the variant G allele was associated with increased *MTNR1B* transcript levels in human islets¹⁷. Because of the functional consequence of rs10830963 C>G, many association studies have examined its effect on the risk of GDM^{16,18-29}. However, these studies presented inconsistent results. To clarify the effect of the *MTNR1B* rs10830963 C>G on the risk of GDM, we therefore performed a meta-analysis with a total of 4,782 GDM patients and 5,605 controls from 12 published case-control studies.

Materials and Methods

Literature search strategy

We searched PubMed, Google Scholar and the Chinese National Knowledge Infrastructure (CNKI) databases for the association studies of *MTNR1B* rs10830963 polymorphism with the risk of GDM. The following key words were used: ‘MTNR1B’ or ‘Melatonin receptor 1B’, ‘gestational diabetes mellitus’ and ‘variation’ or ‘polymorphism’. All studies were published up to May 31, 2016. In addition, we manually searched for additional published studies on this topic in the references cited in the retrieved studies.

The included studies in this meta-analysis had to meet the following criteria: evaluation of the *MTNR1B* rs10830963 C>G polymorphism and GDM risk; case-control study; genotype or allele distribution information in cases and controls for calculating odds ratio (OR) with 95% confidence interval (CI); the study was written in English or Chinese. Accordingly, family-based studies, abstract, case reports, comments and reviews were excluded. If studies had overlapped subjects, only the largest study was included in the final analysis.

Literature evaluation and data extraction

Two professional investigators (Yu XY and Wang QQ) independently reviewed the articles and extracted the data from all eligible publications. The following information was extracted from each included study: first author, year of publication, country, diagnostic criteria, genotyping methods, source of controls, number of cases and controls, genotype or allele distribution data of cases and controls, mean age, mean BMI and *P*-value of the Chi-square goodness of fit test for Hardy-Weinberg equilibrium (HWE) in controls.

Statistical analysis

Deviation of genotype frequencies of the *MTNR1B* rs10830963 C>G polymorphism in controls from HWE was tested by using the Chi-square goodness of fit test, and a *P*-value less than 0.05 was considered a departure from HWE. The odds ratio (OR) and their 95% confidence interval (CI) were used to assess the strength of association between the *MTNR1B* rs10830963 C>G polymorphism and GDM risk. The heterogeneity across studies was assessed by the *Q* test, and was considered significant when a *P*-value less than 0.1³⁰. A fixed-effect model was used to calculate the pooled OR if the heterogeneity was not significant, otherwise, the random-effect model was adopted³¹. The potential source of heterogeneity across the included

studies was explored with meta-regression analyses. Stratified analyses were conducted by ethnicity (Asian and Caucasian). Both Begg's and Egger's tests were used to test for publication bias^{32,33}. A P -value < 0.05 was considered as an indication for the potential presence of publication bias. Sensitivity analyses were done to assess the influence of individual study on the pooled ORs. All analyses were performed by using Stata software, version 12.0 (Stata Corp LP, College Station, TX, USA).

Results

Characteristics of include studies

The flowchart of study selection for this meta-analysis is presented in **Figure 1**. A total of 66 studies were found using our literature search strategy, of which 43 studies were excluded because of duplicates or not on the topic of polymorphisms and GDM risk. After full-text reviews of the remaining 23 articles, 11 studies were excluded for the following reasons: 2 studies were case only studies, 3 studies were review or meta-analysis articles, 6 studies didn't focus on the topic of the *MTNR1B* rs10830963 C>G and GDM risk. Finally, 12 studies with 4,782 GDM patients and 5,605 controls were selected in this meta-analysis. Main characteristics of the included studies were shown in **Table 1**. The genotype frequency distributions of the rs10830963 C>G in controls were in agreement with HWE in all included studies except for the two by Vlassi¹⁸ *et al.* and Liu Q³⁴ *et al.*

Association between the *MTNR1B* rs10830963 C>G and GDM risk

As shown in **Table 2** and **Figure 2~3**, compared with the wild-type homozygous CC genotype, the variant CG heterozygous and GG homozygous genotypes was significantly associated with an increased risk of GDM (CG vs. CC: OR= 1.23, 95% $CI = 1.12-1.34$, $P_{\text{heterogeneity}} = 0.23$; GG vs. CC: OR=1.74, 95% $CI = 1.41-2.15$, $P_{\text{heterogeneity}} = 0.002$), respectively. An obvious heterogeneity across the studies was found in the homozygous genotype comparison.

In the stratified analysis by ethnicity, as shown in **Table 2** and **Figure 2~3**, compared with the homozygous CC genotype, the CG heterozygous genotype and the GG homozygous genotype were significantly associated with elevated risks of GDM in Asians and Caucasians (Asians: CG vs. CC: OR=1.15, 95% $CI = 1.04-1.28$, $P_{\text{heterogeneity}} = 0.74$; GG vs. CC: OR=1.48, 95% $CI = 1.23-1.78$, $P_{\text{heterogeneity}} = 0.08$; Caucasians: CG vs. CC: OR=1.49, 95% $CI = 1.25-1.77$, $P_{\text{heterogeneity}} = 0.28$; GG vs. CC:

OR=2.68, 95% CI = 2.03–3.54, $P_{\text{heterogeneity}} = 0.58$). A modest heterogeneity across the studies was found in the homozygous genotype comparison in Asians. Subsequent leave-one-out analysis found that after removing the study by Wang Y¹⁹ *et al.* or Wang X²⁹ *et al.*, respectively, the heterogeneity among studies almost disappeared in Asian subgroup, suggesting that these two studies may contribute to the observed heterogeneity.

Evaluation of heterogeneity

In this present study, the Q test was used to evaluate the heterogeneity across the included studies and the heterogeneity across studies was found in most of comparisons. We then used the meta-regression analysis to explore the source of heterogeneity and found that the ethnicity might contribute to the heterogeneity across studies in the overall analysis (CG vs. CC: $t=-2.44$, $P = 0.035$; GG vs. CC: $t=3.17$, $P = 0.01$).

Sensitivity analyses

Sensitivity analyses of the association between the *MTNR1B* rs10830963 C>G polymorphism and GDM risk were performed to assess the stability of the pooled ORs under the CG vs.CC and GG vs.CC comparisons. The results showed that no single study dramatically influenced the pooled ORs (**Figure 4** and **Figure 5**).

Publication bias

Both Begg's and Egger's tests were performed to evaluate the publication bias of the included studies. The shape of the funnel plots did not reveal any evidence of obvious asymmetry for all genetic models (**Figure 6** and **Figure 7**), and the Begg's and Egger's tests did not present any significantly statistical evidence of publication bias for any of the genetic models in the overall meta-analysis (CG vs. CC: $P_{\text{Begg's}} = 1.000$ and $P_{\text{Egger's}} = 0.905$, GG vs. CC: $P_{\text{Begg's}} = 0.064$ and $P_{\text{Egger's}} = 0.165$). Neither funnel plots nor Begg's and Egger's tests detected any obvious evidence of publication bias in the subgroup analyses by ethnicity (data not shown).

Table 1 Characteristics of the studies included in the meta-analysis

Author, year (reference)	Country	Diagnostic criteria	Genotyping methods	Controls	No. of case/ control	Genotype distribution (CC/CG/GG)		MAF case/control	Mean age of cases/ controls	Mean BMI of cases/ controls	p_{HWE} for controls
						case	control				
Deng Z,2011(28)	China	ADA	Sequencing	NGT	87/91	23/38/26	31/45/15	0.52/0.41	31.8±4.6/29.7±3.5	23.6±3.0/21.5±2.4	0.84
HuopioH,2013(29)*	Finland	ADA	Sequenom Assay/TaqMan	NGT	533/407	150/265/118	172/185/50	0.47/0.35	32.6/29.9	26.3±4.7/24.1±3.8	0.98
Junior JP 2015	Brazil	ADA	real-time PCR	Healthy	183/183	102/61/20	113/66/4	0.28/0.20	32/29	32.0/25.4	0.11
Kim JY,2011(30)	Korea	ADA	TaqMan	NGT	908/966	217/435/256	294/469/203	0.52/0.45	33.1/32.2	23.3±4.0/21.4±2.9	0.53
Kanthimathi S, 2015	India	IADPSG	Sequenom Assay	NGT	518/910	155/259/104	309/437/164	0.45/0.42	28.1±5.0/26.3±5.5	27.5±2.4/23.3±4.7	0.66
Li C,2013(31)	China	IADPSG	PCR-RFLP	NGT	350/480	113/158/79	172/233/75	0.45/0.40	32.4±4.8/31.9±5.2	25.3±5.2/24.6±4.6	0.79
Liu Q, 2015	China	ADA	TaqMan	NGT	674/674	162/334/178	195/362/117	0.51/0.44	31.6/32.1	24.4/25.2	0.02
Qi J,2013(32)	China	IADPSG	Sequencing	NGT	110/110	25/52/33	37/50/23	0.54/0.44	28.7±3.1/28.1±2.4	NA/NA	0.43
Vlassi M,2012(33)	Greece	ADA	PCR-RFLP	NGT	77/98	30/31/16	56/30/12	0.41/0.28	35.4±4.4/31.3±5.2	25.8±5.1/26.7±6.2	0.02
Vejrazkova D,2014(35)	Czech	WHO guideline	TaqMan	NGT	458/422	169/227/62	206/184/32	0.38/0.29	34.1±6.1/34.8±15.1	24.3±4.9/23.7±4.2	0.48

Wang Y,2011(34)	China	ADA	TaqMan	NGT	700/1029	199/364/137	329/509/191	0.46/0.43	30.0/32.0	21.5/21.7	0.81
Wang X, 2014	China	ADA	PCR-RFLP	NGT	184/235	62/89/33	69/121/45	0.42/0.45	28.2±3.8/27.9±4.1	21.2±1.8/20.7±1.4	0.53

ADA, American Diabetes Association; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; NGT, Normal glucose tolerance; MAF, Minor Allele Frequency; BMI , Body Mass Index ;HWE, Hardy-Weinberg Equilibrium,.* Genotype distribution data was calculated from allele frequency according to the law of HWE.

Table 2 Meta-analysis of the *MTNR1B* rs10830963 polymorphism on GDM risk

Subgroups	CG vs. CC		GG vs. CC	
	OR(95% CI)	<i>P</i> Heterogeneity	OR(95% CI)	<i>P</i> Heterogeneity
Overall	1.23(1.12-1.34)	0.225	1.74(1.41-2.15)	0.002
Ethnicity				
Asian	1.15(1.04-1.28)	0.735	1.48(1.23-1.78)	0.076
Caucasian	1.49(1.25-1.77)	0.282	2.68(2.03-3.54)	0.579

Discussion

GDM could occur when the pancreatic islet β -cells were impaired by an increased insulin resistance during pregnancy³⁵. *MTNR1B* is a G-protein coupled 7-transmembrane receptor and might influence pancreatic β -cells function and fasting plasma glucose (FPG) level^{13,14}. Lyssenko¹⁷ *et al.*'s study showed that the increased expression of *MTNR1B* inhibited β -cells insulin secretion. A study of genetics and quantitative traits analysis of Palmer³⁶ *et al.* revealed a significant association between *MTNR1B* and the glucose disposition index and acute insulin response among T2DM. Meanwhile, experimental studies have confirmed that comparing with the wild-type C allele of rs10830963, the variant G allele caused an increased expression of *MTNR1B*^{20-22,36-38}. To date, a number of case-control studies have been conducted to explore the effects of *MTNR1B* rs10830963 C>G polymorphism on the risk of GDM among different ethnic populations. However, the conclusions are still controversial. Huopio²³ *et al.* found that the G allele of *MTNR1B* rs10830963 was significantly associated with GDM risk by increasing fasting plasma glucose and decreasing insulin secretion. However, Kanthimathi *et al.* reported that there was no significant association between rs10830963 polymorphism and the risk of GDM²⁴. A previous meta-analysis by Zhang *et al.* observed a statistically significant association between the variant CG/GG genotype and GDM risk (OR=1.24, 95% CI =1.14–1.35)³⁹. However, this meta-analysis only included 5 studies (4 studies for Asians and 1 for Caucasians) with 2,122 GDM patients and 2,664 control subjects, and was unable to do the subgroup analysis by ethnicity to reveal the effect of *MTNR1B* rs10830963 C>G polymorphism on GDM risk in different ethnic populations. Our updated

meta-analysis summarized the evidence to date with 4,782 GDM patients and 5,605 controls and found that compared with the wild CC genotype, the variant CG and GG genotype were significantly associated with an increased risk of GDM, respectively. Furthermore, the subgroup analysis by ethnicity revealed that rs10830963 C>G polymorphism was significantly associated with the risk of GDM both in Asians and in Caucasians. Obvious heterogeneity across studies was observed in most comparisons in our meta-analysis. We then used the meta-regression analysis to explore the potential source of heterogeneity and found that the ethnicity might contribute to the observed heterogeneity. The current meta-analysis more comprehensively reflected the relationship between *MTNR1B* rs10830963 and GDM risk.

Some limitations should be point out in the current meta-analysis. First, although the Begg's and Egger's tests did not detect any significantly statistical evidence of publication bias, selection bias could exist because only published case-control studies were included. Second, the small sample size might limit the statistical power of the results in the subgroup analysis by ethnicity. For example, only four eligible studies with 1,251 GDM patients and 1,110 controls were included in the subgroup of Caucasian. Additional studies are warranted to further validate the effect of this functional polymorphism on the risk of GDM. Third, lack of individual-level data prevented us from making further analysis to identify any genotype-environment interaction between rs10830963 C>G and metabolic traits, such as FPG, pancreatic β -cell function, acute insulin response or indices for insulin sensitivity.

In summary, the current meta-analysis indicates that the variant G allele of *MTNR1B* rs10830963 C>G polymorphism may increase the risk of GDM. Given the limitations mentioned above, further large and well-designed studies of different ethnic populations are warranted to validate our findings.

Additional information

Acknowledgments

This study was supported by the Scientific Research Project of Education Department, Guangxi, China (grant No.KY2015YB223), the Science Research and Technology Development Project, Guangxi, China (grant No. 1412-4004-1-15).

Competing financial interests: No competing financial interests exist.

Tables and Figures:

Table 1 Characteristics of the studies included in the meta-analysis

Table 2 Meta-analysis of the MTNR1B rs10830963 polymorphism on GDM risk

Figure 1 Flow chart of the process of identification of eligible studies

Figure 2 Forest plot risk of GDM associated with the MTNR1B rs10830963 (CG vs. CC)

Figure 3 Forest plot risk of GDM associated with the MTNR1B rs10830963 (GG vs. CC)

Figure 4 Sensitivity analyses of the association between the MTNR1B rs10830963 C>G GDM risk under the CG vs.CC comparison

Figure 5 Sensitivity analyses of the association between the MTNR1B rs10830963 C>G GDM risk under the GG vs.CC comparison

Figure 6 Funnel plot analysis to detect publication bias (CG vs. CC)

Figure 7 Funnel plot analysis to detect publication bias (GG vs. CC)

Reference

1. Gestational diabetes mellitus. *Diabetes care*. Jan 2004;27 Suppl 1:S88-90.
2. Galtier F. Definition, epidemiology, risk factors. *Diabetes & metabolism*. Dec 2010;36(6 Pt 2):628-651.
3. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet*. May 23 2009;373(9677):1773-1779.
4. Nicotra F, Molinari C, Dozio N, et al. Screening for gestational diabetes in the Lombardy region: A population-based study. *Diabetes & metabolism*. Sep 2015;41(4):319-325.
5. Martin KE, Grivell RM, Yelland LN, Dodd JM. The influence of maternal BMI and gestational diabetes on pregnancy outcome. *Diabetes research and clinical practice*. Jun 2015;108(3):508-513.
6. Whyte K, Kelly H, O'Dwyer V, Gibbs M, O'Higgins A, Turner MJ. Offspring birth weight and maternal fasting lipids in women screened for gestational diabetes mellitus (GDM). *European journal of obstetrics, gynecology, and reproductive biology*. Sep 2013;170(1):67-70.
7. Leng J, Shao P, Zhang C, et al. Prevalence of gestational diabetes mellitus and its risk factors in Chinese pregnant women: a prospective population-based study in Tianjin, China. *PloS one*. 2015;10(3):e0121029.
8. Chu SY, Callaghan WM, Kim SY, et al. Maternal obesity and risk of gestational diabetes mellitus. *Diabetes care*. Aug 2007;30(8):2070-2076.
9. Rhee SY, Kim JY, Woo JT, Kim YS, Kim SH. Familial clustering of type 2 diabetes in Korean women with gestational diabetes mellitus. *The Korean journal of internal medicine*. Sep 2010;25(3):269-272.
10. Zhang C, Bao W, Rong Y, et al. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. *Human reproduction update*. Jul-Aug 2013;19(4):376-390.
11. Anzaku AS, Musa J. Prevalence and associated risk factors for gestational diabetes in Jos, North-central, Nigeria. *Archives of gynecology and obstetrics*. May 2013;287(5):859-863.
12. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. *The Journal of clinical endocrinology and metabolism*. Mar 2001;86(3):989-993.
13. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. *Progress in neurobiology*. Jul 2008;85(3):335-353.
14. Ramracheya RD, Muller DS, Squires PE, et al. Function and expression of melatonin receptors on human pancreatic islets. *Journal of pineal research*. Apr 2008;44(3):273-279.
15. Van Cauter E. Putative roles of melatonin in glucose regulation. *Therapie*. Sep-Oct 1998;53(5):467-472.

16. Ren J, Xiang AH, Trigo E, et al. Genetic variation in MTNR1B is associated with gestational diabetes mellitus and contributes only to the absolute level of beta cell compensation in Mexican Americans. *Diabetologia*. Jul 2014;57(7):1391-1399.
17. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. *Nature genetics*. Jan 2009;41(1):82-88.
18. Vlassi M, Gazouli M, Paltoglou G, et al. The rs10830963 variant of melatonin receptor MTNR1B is associated with increased risk for gestational diabetes mellitus in a Greek population. *Hormones (Athens)*. Jan-Mar 2012;11(1):70-76.
19. Wang Y, Nie M, Li W, et al. Association of six single nucleotide polymorphisms with gestational diabetes mellitus in a Chinese population. *PloS one*. 2011;6(11):e26953.
20. Kim JY, Cheong HS, Park BL, et al. Melatonin receptor 1 B polymorphisms associated with the risk of gestational diabetes mellitus. *BMC medical genetics*. 2011;12:82.
21. Li C, Qiao B, Zhan Y, et al. Association between genetic variations in MTNR1A and MTNR1B genes and gestational diabetes mellitus in Han Chinese women. *Gynecologic and obstetric investigation*. 2013;76(4):221-227.
22. Vejrazkova D, Lukasova P, Vankova M, et al. MTNR1B Genetic Variability Is Associated with Gestational Diabetes in Czech Women. *International journal of endocrinology*. 2014;2014:508923.
23. Huopio H, Cederberg H, Vangipurapu J, et al. Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. *European journal of endocrinology / European Federation of Endocrine Societies*. Sep 2013;169(3):291-297.
24. Kanthimathi S, Chidambaram M, Liju S, et al. Identification of Genetic Variants of Gestational Diabetes in South Indians. *Diabetes technology & therapeutics*. Jul 2015;17(7):462-467.
25. Junior JP, Frigeri HR, Dos Santos-Weiss IC, et al. The MTNR1B gene polymorphism rs10830963 is associated with gestational diabetes in a Brazilian population. *Gene*. Aug 15 2015;568(1):114-115.
26. Liu Q, Huang Z, Li H, Bai J, Liu X, Ye H. Relationship between melatonin receptor 1B (rs10830963 and rs1387153) with gestational diabetes mellitus: a case-control study and meta-analysis. *Archives of gynecology and obstetrics*. Jul 2016;294(1):55-61.
27. Qi J, Hu G, Wang J. Correlation study between single nucleotide polymorphism of melatonin receptor LB gene and gestational diabetes mellitus. *China Medical Herald*. 2015;10(3):4-6.
28. Deng Z, Shu Q, Chen Y, et al. Association of genetic variant rs10830963 of melatonin receptor 1B gene in women with gestational diabetes mellitus. *Chin J perinat Med*. 2011;14(11):666-669.
29. Wang X, Sun S, Bao L. Association between gene polymorphism of Melatonin receptor 1B and gestational diabetes mellitus. *Chinese Journal of Diabetes*. 2014;22(5):398-400.
30. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Annals of internal medicine*. Nov 1 1997;127(9):820-826.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials*. Sep 1986;7(3):177-188.
32. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. Dec 1994;50(4):1088-1101.
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. Sep 13 1997;315(7109):629-634.
34. Liu Q, Huang Z, Li H, Bai J, Liu X, Ye H. Relationship between melatonin receptor 1B (rs10830963 and rs1387153) with gestational diabetes mellitus: a case-control study and meta-analysis. *Archives of gynecology and obstetrics*. Nov 12 2015.
35. Lambrinoudaki I, Vlachou SA, Creatsas G. Genetics in gestational diabetes mellitus: association with incidence, severity, pregnancy outcome and response to treatment. *Current diabetes reviews*. Nov 2010;6(6):393-399.
36. Palmer ND, Goodarzi MO, Langefeld CD, et al. Genetic Variants Associated With Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium. *Diabetes*. May 2015;64(5):1853-1866.
37. Salman M, Dasgupta S, Cholendra A, et al. MTNR1B gene polymorphisms and susceptibility to Type 2 Diabetes: A pilot study in South Indians. *Gene*. Jul 25 2015;566(2):189-193.
38. Semiz S, Dujic T, Velija-Asimi Z, et al. Effects of melatonin receptor 1B gene variation on glucose control in population from Bosnia and Herzegovina. *Experimental and clinical*

- endocrinology & diabetes* : official journal, German Society of Endocrinology [and] German Diabetes Association. Jun 2014;122(6):350-355.
39. Zhang Y, Sun CM, Hu XQ, Zhao Y. Relationship between melatonin receptor 1B and insulin receptor substrate 1 polymorphisms with gestational diabetes mellitus: a systematic review and meta-analysis. *Scientific reports*. 2014;4:6113.

Figure 1 Flow chart of the process of identification of eligible studies

Figure 2 Forest plot risk of GDM associated with the MTNR1B rs10830963 (CG vs. CC)

Figure 3 Forest plot risk of GDM associated with the MTNR1B rs10830963 (GG vs. CC)

Figure 4 Sensitivity analyses of the association between the *MTNR1B* rs10830963 C>G GDM risk under the CG vs.CC comparison

Figure 5 Sensitivity analyses of the association between the *MTNR1B* rs10830963 C>G GDM risk under the GG vs.CC comparison

Figure 6 Begg's funnel plot for publication bias test (CG vs. CC)

Figure 7 Begg's funnel plot for publication bias test (GG vs. CC)